Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms

Multiple Sclerosis Clinical Trial

Official title:

A Phase II, Double-blind, Randomized, Placebocontrolled, Parallel-group, Single-center Study to Evaluate the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in Multiple Sclerosis (MS) Patients With Spasticity-related Symptoms

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03005119
• Other study ID #: CS-101
• Status: Not yet recruiting
• Phase: Phase 2
• First received: December 25, 2016
• Last updated: September 26, 2017
• Start date: March 1, 2018
• Est. completion date: December 2018

Study information

• Verified date: September 2017
• Source: PhytoTech Therapeutics, Ltd.
• Contact: Hagit Sacks
• Phone: +972 3 6449599
• Email: hsacks[@]mmjphytotech.com.au
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and tolerability of oral administration of PTL201 for relief of spasticity-related symptoms in 70 MS patients and to evaluate the efficacy of oral administration of PTL201 in relief of spasticity-related symptoms in MS patients. The pharmacokinetics of PTL201 in comparison to buccally administered Sativex will be evaluated in sub-study prior to the efficacy study.

Description:

The study will be comprised of the following parts:

1. Pharmacokinetics (PK) sub-study:

A 7-day baseline observation period. Randomized cross-over treatments (Sativex, PTL201), performed at minimum 7-day washout.

Follow up - one week after the last dosing session.

2. Efficacy study:

A 7-day baseline observation period. Single-blind responder phase - 4 weeks. Randomized, double-blind, placebo-controlled treatment phase - 4 weeks Follow up - two weeks.

Subjects participating in the pharmacokinetic sub-study will be allowed to participate in the efficacy study and will not be required to repeat the 7-day observation period of the efficacy study.

Doses will be titrated over a one-week period until reaching maximum tolerated dose (MTD) for each participant The MTD will be self administered for three weeks thereafter. Participants demonstrating response to treatment will continue self administering daily PTL201 treatment or placebo, for an additional four weeks. Participants will keep a daily diary.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 70
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Patient (male or female), age 18-65 years

2. Definite diagnosis of MS, according to McDonald 2010 criteria, at least six months prior to enrollment, with MS associated spasticity for at least 3 months prior to enrollment

1. Patients suffer from moderate to-severe MS-associated spasticity (=4 sNRS), with no adequate response to traditional antispastic medications

2. EDSS score: 4 = EDSS = 6; functional motor score =3.0 Safety, tolerability and efficacy of PTL201 in reducing multiple sclerosis-associated spasticity-related symptoms

3. Moderate to severe spasticity in at least two districts of upper and/or lower limbs

3. Anti-spasticity agent(s) and/or disease-modifying medications maintained at a stable dose for 30 days prior to and throughout the study

4. Patients able to self-score spasticity

5. Absence of clinical or neuroradiological relapses from at least three months prior to study entry

6. Willingness and ability to provide written informed consent

7. Willingness and ability to comply with all study requirements

8. Inclusion criteria for placebo-controlled treatment phase:

No major protocol violations were recorded for the patient in the responder phase and at least 20% improvement in sNRS

Exclusion Criteria:

1. Concomitant disease or disorder with spasticity-like symptoms or that may influence the subject's level of spasticity, or medical history suggesting that relapse/remission is likely to recur during the study or expected to influence spasticity

2. Currently using or used cannabis or cannabinoid-based medications within 30 days of study entry and is unwilling to abstain from using them for the duration of the study.

3. Concurrent significant psychiatric, renal, hepatic,cardiovascular or convulsive disorders

4. History or immediate family history of schizophrenia, other psychotic illness, severe personality disorder, or other significant psychiatric disorder other than depression related to MS/MS-associated spasticity.

5. Any known or suspected history of substance abuse/dependence disorder (including opiate abuse),current heavy alcohol consumption, current use of illicit drug, or current non-prescribed use of any prescription drug.

6. Poorly controlled epilepsy or recurrent seizures (i.e., one or more seizures in the past year).

7. Known or suspected hypersensitivity to cannabinoids or to any of the excipients of the study drugs.

8. Myocardial infarction or clinically significant cardiac dysfunction within 12 months of study entry or a cardiac disorder that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction

9. Female patients of child-bearing potential and male patients whose partner is of childbearing potential, unless willing to ensure that they or their partner use effective contraception throughout the study and for three months thereafter

10. Female patient who is pregnant, lactating, or planning pregnancy during the course of the study or within the 3 months thereafter.

11. Any other significant diseases or disorder, which, in the opinion of the investigator, participation in the study may either put the patient at risk or may influence the result of the study, or the patient's ability to participate in the study.

12. Travel outside the country planned during the study.

13. Unwilling to abstain from donating blood during the study.

14. Patients previously randomized into a cannabinoid-based clinical trial for MS pain and spasticity within 6 months of study entry.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Drug:
• PTL201
Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD
• Placebo Oral Capsule
Placebo seamless gelatin matrix green beads containing excipients only

Locations

Country	Name	City	State
Israel	Sheba medical center	Tel Hashomer, Ramat gan

Sponsors (1)

Lead Sponsor	Collaborator
PhytoTech Therapeutics, Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Combined modified Ashworth score (cMAS) and MS walking scale 12 (MSWS-12) assessments, posturography measure, Selected spatio-temporal parameters of gait		at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
Primary	Incidence of study treatment-related adverse events (AE)		10 weeks (70 days) from beginning of treatment to end of follow-up
Primary	Change in sNRS scores from randomization to end of placebo-controlled treatment phase		during the 4 weeks (28 days) placebo-controlled treatment period
Secondary	Incidence of all AEs		during 10 week treatment plus follow up period
Secondary	Percent change in walking velocity		during 4 weeks placebo-controlled treatment period
Secondary	Clinical Global Impression Improvement (CGI-I) assessment using a 7-point scale condition		at randomization (day 29) and the end of placebo-controlled treatment phase (day 57)
Secondary	Cadence (steps/min) assessment		at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
Secondary	Stride length (cm) assessment		at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
Secondary	pNRS assessment		at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
Secondary	Spasm frequency assessment		at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
Secondary	Sleep disturbance assessment		at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
Secondary	Assessment of clinical gait measures	Timed (sec) 25 foot walk test (T25FW)	at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)
Secondary	Assessment of clinical gait measures	Timed (sec) up and go test (TUG)	at baseline (day 1) end of responder phase (day 29) and end of placebo-controlled treatment phase (day 57)